NO20014869D0 - Vevsinhibitor av matriksmetallproteinase type-1 (TIMP-1) som en kreftmarkör - Google Patents

Vevsinhibitor av matriksmetallproteinase type-1 (TIMP-1) som en kreftmarkör

Info

Publication number
NO20014869D0
NO20014869D0 NO20014869A NO20014869A NO20014869D0 NO 20014869 D0 NO20014869 D0 NO 20014869D0 NO 20014869 A NO20014869 A NO 20014869A NO 20014869 A NO20014869 A NO 20014869A NO 20014869 D0 NO20014869 D0 NO 20014869D0
Authority
NO
Norway
Prior art keywords
timp
matrix metal
cancer marker
tissue inhibitor
metal proteinase
Prior art date
Application number
NO20014869A
Other languages
English (en)
Other versions
NO20014869L (no
NO329725B1 (no
Inventor
Mads Holten-Andersen
Ross W Stephens
Hans Joergen Nielsen
Jarle Christensen Ib
Nils Bruenner
Original Assignee
Rigshospitalet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigshospitalet filed Critical Rigshospitalet
Publication of NO20014869D0 publication Critical patent/NO20014869D0/no
Publication of NO20014869L publication Critical patent/NO20014869L/no
Publication of NO329725B1 publication Critical patent/NO329725B1/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G01N2333/96491—Metalloendopeptidases (3.4.24) with definite EC number
    • G01N2333/96494—Matrix metalloproteases, e. g. 3.4.24.7

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20014869A 1999-04-09 2001-10-05 Fremgangsmate for bestemmelse av kolorektal kreft eller metastatisk brystkreft basert pa bestemmelse av konsentrasjonenTIMP-1 i plasmaprover NO329725B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA199900476 1999-04-09
PCT/DK2000/000170 WO2000062070A2 (en) 1999-04-09 2000-04-10 Tissue inhibitor of matrix metalloproteinases type-1 (timp-1) as a cancer marker

Publications (3)

Publication Number Publication Date
NO20014869D0 true NO20014869D0 (no) 2001-10-05
NO20014869L NO20014869L (no) 2001-12-04
NO329725B1 NO329725B1 (no) 2010-12-06

Family

ID=8093987

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20014869A NO329725B1 (no) 1999-04-09 2001-10-05 Fremgangsmate for bestemmelse av kolorektal kreft eller metastatisk brystkreft basert pa bestemmelse av konsentrasjonenTIMP-1 i plasmaprover

Country Status (11)

Country Link
US (6) US7108983B1 (no)
EP (2) EP1619206A3 (no)
JP (2) JP4638608B2 (no)
AT (1) ATE298890T1 (no)
AU (1) AU771309B2 (no)
CA (2) CA2652131A1 (no)
DE (1) DE60021068T2 (no)
ES (1) ES2244417T3 (no)
NO (1) NO329725B1 (no)
NZ (1) NZ515311A (no)
WO (1) WO2000062070A2 (no)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060154245A1 (en) * 1999-04-09 2006-07-13 Rigshospitalet Method for detecting, screening and/or montoring a cancer in individual
US7374886B2 (en) * 1999-04-09 2008-05-20 Rigshospitalet Tissue inhibitor of matrix metalloproteinases type-1 (TIMP-1) as a cancer marker and postoperative marker for minimal residual disease or recurrent disease in patients with a prior history of cancer
EP1619206A3 (en) * 1999-04-09 2006-02-15 Rigshospitalet Tissue inhibitor of matrix metallproteinases type-1 (TIMP-1) as a cancer marker
DE60237969D1 (de) 2001-04-24 2010-11-25 Bayer Corp Menschliche antikörper gegen timp-1
WO2003087830A2 (en) * 2002-04-08 2003-10-23 Rigshospitalet Timp-1 as a postoperative marker for recurrent cancer
AU2003269837B9 (en) * 2002-09-26 2009-07-30 Hvidovre Hospital A method for detecting, screening and/or monitoring a cancer in an individual
AU2004227018A1 (en) * 2003-04-08 2004-10-21 Colotech A/S A method for detection of colorectal cancer in human samples
AU2005229492A1 (en) * 2004-03-30 2005-10-13 Rigshospitalet Improvements in cancer treatment and cancer treatment efficacy prediction by blocking and detecting protease inhibitors
US20100196889A1 (en) * 2006-11-13 2010-08-05 Bankaitis-Davis Danute M Gene Expression Profiling for Identification, Monitoring and Treatment of Colorectal Cancer
JP2010519529A (ja) * 2007-02-23 2010-06-03 プレディクティブ バイオサイエンシーズ コーポレイション 臨床的介入を指向する診断方法
EP2145190A1 (en) * 2007-05-10 2010-01-20 Roche Diagnostics GmbH Use of timp-1 as a marker for colorectal cancer
FR2919061B1 (fr) * 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de la plastine-i pour le diagnostic in vitro du cancer colorectal.
FR2919062B1 (fr) * 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de l'aminoacylase 1 pour le diagnostic in vitro du cancer colorectal.
FR2919060B1 (fr) * 2007-07-19 2012-11-30 Biomerieux Sa Procede de dosage de l'ezrine pour le diagnostic in vitro du cancer colorectal.
FR2919065B1 (fr) * 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de l'apolipoproteine ai pour le diagnostic in vitro du cancer colorectal
FR2919064B1 (fr) * 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de l'apolipoproteine all pour le diagnostic in vitro du cancer colorectal
ES2565512T3 (es) * 2007-07-19 2016-04-05 bioMérieux Procedimiento de ensayo de la proteína de unión a ácidos grasos del hígado, de ACE y de CA19-9 para el diagnóstico in vitro del cáncer colorrectal
FR2919063B1 (fr) * 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage du leucocyte elastase inhibitor pour le diagnostic in vitro du cancer colorectal.
US20090186370A1 (en) * 2008-01-18 2009-07-23 Ogle Matthew F Diagnostic biomarkers for vascular aneurysm
NZ586909A (en) 2008-01-23 2012-05-25 Herlev Hospital Ykl-40 as a general marker for non-specific disease
WO2009149714A1 (en) * 2008-06-11 2009-12-17 Bruenner Nils Aage Selection of colorectal cancer patients for neo-adjuvant and adjuvant systemic anti-cancer treatment
FR2933773B1 (fr) * 2008-07-10 2013-02-15 Biomerieux Sa Procede de dosage de la proteine disulfide isomerase pour le diagnostic in vitro du cancer colorectal
JP2012502285A (ja) 2008-09-15 2012-01-26 ヘルレフ ホスピタル 消化管癌のマーカーとしてのｙｋｌ−４０
DE102009015784A1 (de) * 2009-03-31 2010-12-02 Siemens Aktiengesellschaft In-vitro-Verfahren zur Diagnostik von Tumorerkrankungen
US9141756B1 (en) 2010-07-20 2015-09-22 University Of Southern California Multi-scale complex systems transdisciplinary analysis of response to therapy
JP6182308B2 (ja) * 2012-11-13 2017-08-16 株式会社エイアンドティー 前立腺癌の鑑別診断に用いるための泳動波形データの処理方法
WO2016164815A1 (en) 2015-04-10 2016-10-13 Applied Proteomics, Inc. Protein biomarker panels for detecting colorectal cancer and advanced adenoma
US20210148894A1 (en) * 2018-04-13 2021-05-20 Bionomics Limited Method of monitoring response to a treatment
US20220304972A1 (en) * 2019-08-23 2022-09-29 Sumitomo Dainippon Pharma Co., Ltd. Combination therapy and biomarker indicating efficacy thereof

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US111359A (en) * 1871-01-31 Improvement in sewing-machines
US62070A (en) * 1867-02-12 And jeremiah kimbrough
US234776A (en) * 1880-11-23 Belt-coupling
US2086085A (en) * 1935-05-14 1937-07-06 Handley Page Ltd Aircraft control gear
US3087830A (en) * 1958-12-17 1963-04-30 Schuller Werner Hugo Wilhelm Method and apparatus for producing a dry mat sheet
US3006671A (en) * 1959-08-03 1961-10-31 Gen Precision Inc Internal staking
US6271352B1 (en) 1985-07-12 2001-08-07 Fonden Til Fremme Af Eksperimentel Cancerforskning PAI-1 determination and use thereof
US5356817A (en) * 1988-06-09 1994-10-18 Yale University Methods for detecting the onset, progression and regression of gynecologic cancers
FR2657700A1 (fr) 1990-01-26 1991-08-02 Thomson Csf Modulateur electrooptique spatial et applications.
US5324634A (en) 1992-03-31 1994-06-28 The Research Foundation Of State University Of New York Diagnostic tests measuring gelatinase/inhibitor complexes for detection of aggressive and metastatic cancer
JPH0813654A (ja) 1994-07-01 1996-01-16 Sekisui House Ltd 断熱壁下地パネルの施工構造
US5569458A (en) * 1994-09-14 1996-10-29 Greenberg; Mike Nutritional formula
JPH08136548A (ja) * 1994-11-11 1996-05-31 Morinaga & Co Ltd 泌尿器癌の診断法
JP2864219B2 (ja) * 1995-02-20 1999-03-03 富士薬品工業株式会社 遊離の活性型マトリックスメタロプロテアーゼ類の分別定量法
US5643752A (en) 1996-01-18 1997-07-01 Incyte Pharmaceuticals, Inc. Tissue inhibitor of metalloproteinases
GB9607287D0 (en) * 1996-04-09 1996-06-12 British Biotech Pharm Diagnosis method
JPH10287700A (ja) * 1997-04-10 1998-10-27 Fuji Yakuhin Kogyo Kk 活性型マトリライシン（ｍｍｐ−７）に対する抗体及びそれを用いた免疫学的測定法
US5906811A (en) * 1997-06-27 1999-05-25 Thione International, Inc. Intra-oral antioxidant preparations
CN1236102A (zh) 1998-05-20 1999-11-24 徐国光 唾液癌胚抗原快速检测试剂
AU6511199A (en) 1998-10-08 2000-04-26 Calbiochem Novabiochem Corporation Diagnostic assay for matrix metalloproteinase 9 and use thereof
US7374886B2 (en) 1999-04-09 2008-05-20 Rigshospitalet Tissue inhibitor of matrix metalloproteinases type-1 (TIMP-1) as a cancer marker and postoperative marker for minimal residual disease or recurrent disease in patients with a prior history of cancer
EP1619206A3 (en) 1999-04-09 2006-02-15 Rigshospitalet Tissue inhibitor of matrix metallproteinases type-1 (TIMP-1) as a cancer marker
US20060154245A1 (en) 1999-04-09 2006-07-13 Rigshospitalet Method for detecting, screening and/or montoring a cancer in individual
US6630163B1 (en) * 1999-04-22 2003-10-07 Howard Murad Method of treating dermatological disorders with fruit extracts
JP2003506715A (ja) 1999-08-06 2003-02-18 アイエムアイ・インターナショナル・メディカル・イノベーションズ・インコーポレイテッド 色に基づく生化学的及び免疫学的アッセイにおける分光学的測定
US7347886B2 (en) * 2000-01-10 2008-03-25 Sulzer Chemtech Ag Method for introducing additives into fluids
JP2004528814A (ja) 2000-10-13 2004-09-24 チルドレンズ メディカル センター コーポレーション 組織再構築関連状態についての非侵襲性酵素スクリーニング
WO2002034776A2 (en) 2000-10-26 2002-05-02 K.U.Leuven Research And Development Epitopes of pai-1
EP1356298B1 (en) 2000-11-30 2011-05-18 Crawford Healthcare Holdings Limited Diagnosis of disease
DE60237969D1 (de) 2001-04-24 2010-11-25 Bayer Corp Menschliche antikörper gegen timp-1
US6815181B2 (en) 2001-07-09 2004-11-09 Applera Corporation Nucleic acid molecules encoding human secreted hemopexin-related proteins
EP1527189A4 (en) 2001-07-18 2006-03-15 American Nat Red Cross MUTANTS OF PROTEINASE INHIBITORS AND ITS APPLICATIONS
KR100475642B1 (ko) 2001-12-29 2005-03-10 한국생명공학연구원 암 발생 및 전이에 관여하는 단백질의 당쇄 변화를측정하여 암을 진단하는 방법 및 이를 이용한 진단킷트
WO2003087830A2 (en) 2002-04-08 2003-10-23 Rigshospitalet Timp-1 as a postoperative marker for recurrent cancer
EP1382969A1 (en) 2002-07-17 2004-01-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Diagnosis and prevention of cancer cell invasion
AU2003269837B9 (en) 2002-09-26 2009-07-30 Hvidovre Hospital A method for detecting, screening and/or monitoring a cancer in an individual
US20040157278A1 (en) 2002-12-13 2004-08-12 Bayer Corporation Detection methods using TIMP 1
CA2532722C (en) 2003-07-17 2016-10-04 Pacific Edge Biotechnology, Ltd. Cystatin sn (cst1) and other markers for detection of gastric cancer
AU2005229492A1 (en) * 2004-03-30 2005-10-13 Rigshospitalet Improvements in cancer treatment and cancer treatment efficacy prediction by blocking and detecting protease inhibitors

Also Published As

Publication number Publication date
US20070020707A1 (en) 2007-01-25
EP1619206A2 (en) 2006-01-25
US20080261246A1 (en) 2008-10-23
JP4638608B2 (ja) 2011-02-23
DE60021068T2 (de) 2006-05-18
JP2002541481A (ja) 2002-12-03
AU771309B2 (en) 2004-03-18
AU3655600A (en) 2000-11-14
US20090035794A1 (en) 2009-02-05
ES2244417T3 (es) 2005-12-16
US20110294148A1 (en) 2011-12-01
EP1171771B1 (en) 2005-06-29
WO2000062070A2 (en) 2000-10-19
JP2010266455A (ja) 2010-11-25
CA2652131A1 (en) 2000-10-19
ATE298890T1 (de) 2005-07-15
CA2366682A1 (en) 2000-10-19
US7807379B2 (en) 2010-10-05
WO2000062070A3 (en) 2001-01-25
NZ515311A (en) 2002-11-26
NO20014869L (no) 2001-12-04
DE60021068D1 (de) 2005-08-04
EP1619206A3 (en) 2006-02-15
CA2366682C (en) 2009-06-23
US20110060529A1 (en) 2011-03-10
NO329725B1 (no) 2010-12-06
EP1171771A2 (en) 2002-01-16
US7108983B1 (en) 2006-09-19

Similar Documents

Publication Publication Date Title
NO20014869D0 (no) Vevsinhibitor av matriksmetallproteinase type-1 (TIMP-1) som en kreftmarkör
NZ575886A (en) Serine or cysteine proteinase inhibitor clade H (SERPHINH1) as a marker for detection of gastric cancer
ATE306553T1 (de) Verwendung von hydroxylphenyl pyruvate dioxygenase ( hppd ) inhibitoren als selektionsmittel für pflanzentransformation
YU17402A (sh) Nova spiroheterociklična jedinjenja upotrebljiva kao reverzibilni inhibitori cisteinskih proteaza
GB2392978A (en) Identification and use of conserved noncoding sequences
ES2162277T3 (es) Sustratos e inhibidores de enzimas proteoliticos.
PT871454E (pt) Inibidores fosforosos que contem protease de cisteina e de serina
MXPA01011182A (es) Metodos, composiciones y conjuntos para indicador biologico de esterilizacion.
JPS6430599A (en) Method for measuring serine protease and protease inhibitor
DK1353948T3 (da) Oplöselige biologiske analoge til bata-amyloidpeptid
ES2168816T3 (es) Cemento de inyeccion que contiene inhibidores de la corrosion.
DE69824839D1 (de) Verfahren zur herstellung von 2-aryl-3-aryl-5-halogen-pyridinen, verwendbar als cox-2 inhibitoren
DE10192412D2 (de) Verfahren zur Verbesserung des Regelverhaltens eines ABS
EP1349961A4 (en) PROCESS FOR DETERMINING THE BIOLOGICAL EFFECTS OF COMPOUNDS ON GENE EXPRESSION
WO2003087830A3 (en) Timp-1 as a postoperative marker for recurrent cancer
AU2001254634A1 (en) Use of neuregulin-beta as an indicator and/or target
WO2001063293A3 (en) Diagnosis and treatment of schizophrenia
WO2002044417A3 (en) Expression analysis of inhibitor of differentiation nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
PL1664330T3 (pl) Badanie krwi i moczu
ATE323173T1 (de) Nährboden zum nachweis und/oder zur unterscheidung von enterokokken
DK0760482T3 (da) Metode til bedømmelse af udryddelse af H. Pylori på basis af graden af ændringer i pepsinogen I/II-forholdet
NO20012308D0 (no) Kombinasjon av riluzol og alfatokoferol
AU2003230916A1 (en) Ex vivo method for determination of cetp activity and efficacy of heart disease treatment
DE60118350D1 (de) Fluoreszenz-verfahren zum nachweis von proteasen oder peptidasen
SE0100126L (sv) Farmaceutisk komposition

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: PLOUGMANN & VINGTOFT POSTBOKS 1003 SENTRUM OSLO, 0

MM1K Lapsed by not paying the annual fees